Invest in the Future of MSK Care
BodySync is an AI-powered platform transforming how MSK clinics create and deliver treatment plans.
Overview
BodySync uses AI to analyse the latest evidence and generate patient-specific, evidence-based treatment plans built directly from the clinician assessment.
Clinics save time, patients stay engaged, and treatment quality becomes consistently high across teams - increasing outcomes, efficiency, and revenue.
The Problem
Outdated Methods
With little opportunity to review latest evidence, many rely on familiar treatment for years, often applying the same approach regardless of individual patient needs, resulting in patients receiving sub-optimal care.
Lack of Long Term Treatment Planning
Clinicians face relentless time pressure with limited tools and knowledge for creating long-term treatment plans. Planning week to week results in an unclear pathway for patients, increasing early drop off from treatment.
Inconsistent Outcomes
Variable training in exercise progression leads to inconsistent outcomes, reduced engagement, and higher drop-out rates due to lack of structure and measurable goals. Most clinicians don't even understand how set and rep ranges should vary depending on the desired goals. The result is fragmented care and lost revenue opportunities.
Business Skills Gap
Most MSK practitioners have little formal education in business or practice management. Many transition from the NHS where treatment is free, creating anxiety around discussing costs or scheduling appropriate follow-ups, resulting in significant underbooking of follow up sessions, leading to reduced patient outcomes and reduced clinic revenue.
Limited Software Solutions
Existing exercise-prescription software still depends on clinicians to select exercises, define dosage, and plan progressions-decisions requiring both time and specialist knowledge that many don't have.
The Solution
BodySync transforms treatment planning into an intelligent, evidence-based process by combining clinician assessment with AI that analyzes the latest research to generate the most effective, patient-specific treatment plans.
Combines clinician assessment with AI analysis of latest peer-reviewed research
Patient specific plan, including tailored use of equipment patient has access to
Tailored to clinic services and equipment
Objective recommendations for number and frequency of treatment sessions
Fully referenced to support clinician education and professional development
Clear summaries, patient education, measurable milestones, and goal tracking
Built-in exercise progressions tailored to the desired outcomes
Treatment plans take the patient all the way to return to play/activities, not just to out of pain
Quickly and easy to edit at any time throughout the patient journey
Treatment plan can be emailed to the patient as a full plan, or separated into phases
Market Opportunity
Private Sector
Private practice across physiotherapy, osteopathy, chiropractic, and sports rehabilitation
English-speaking, MSK-specialist markets
(£15.7m–£36.4m including non English speaking countries)
At 5–10% market penetration (6,000–12,000 users) @ £75/user/month
The UK private hospital market (not included above), includes 600+ mid-to-large private hospitals and over 2,000 clinic-level facilities. This represents a meaningful additional addressable market for BodySync beyond individual private clinics.
NHS
Hospitals and primary care units
GP Surgeries and general acute hospitals
6419 GP Surgeries: £500k/year at 10% uptake @ £75/first contact practitioner/month
220 General Acute Hospitals: £700k–£800k at 20% uptake @ £800–£1,000/month
While BodySync's immediate focus is on the private MSK sector, the platform has been designed for easy adaption to the NHS. Its data-driven foundation is designed to align with NHS priorities for consistency, efficiency, and outcomes. Future integration into NHS MSK services represents a major expansion opportunity once commercial traction is established.
Traction & Validation
Business Model
B2B Subscription Model
BodySync operates on a B2B subscription model, licensed per clinician. Each clinic pays a monthly fee per user, with tiered pricing based on clinician count.
Licensing to NHS trusts and the private hospital sectors follows an organizational subscription model, with pricing structured to accommodate multiple departments and practitioners within each facility.
Future Revenue Streams:
- Membership sales to Super Plan access
- Commercialisation of Ask BodySync - our AI Mentor giving evidence based answers to healthcare questions
- Integration partnerships
- Data insights and analytics
- Professional education programs
- Benchmarking services
- Research collaborations
Revenue will grow organically through clinic-level licenses and wider team adoption. As data tagging and outcome tracking features develop, additional opportunities emerge for professional education, benchmarking, and research collaborations.
This pricing structure supports a smooth transition from single-clinician adoption to full clinic implementation, maintaining healthy margins while scaling efficiently.
Roadmap
2024
Development & Validation
- •Identified major inefficiencies and inconsistencies in MSK treatment planning
- •Conducted market research and clinician interviews to validate the problem
- •Defined key user needs - save time, standardise care, improve outcomes, and increase patient return visits
- •Designed early product concept and completed feasibility assessment
2025
Launch Phase
- •Built the minimum viable product (MVP) using real clinician input
- •Internal testing completed across our own clinics, with refinements based on user feedback
- •Conducted research into clinic readiness, adoption barriers, and patient engagement
- •Integrated with major practice management systems (e.g., Cliniko)
- •Initiated discussions for integration with additional PMS and exercise prescription platforms
- •Usability and workflow testing underway in 25 clinics with 40+ individual users
- •SEIS funding pending approval to accelerate commercial rollout
2026
Growth Phase
- •Convert pilot clinics into paying customers
- •Expand marketing to the wider UK
- •Implement SEIS-funded product refinements based on pilot feedback
- •Launch Super Plan Tagging System - enabling AI self-learning and standardised treatment pathways
- •Establish formal integration partnerships with leading digital health providers
- •Begin commercialisation of Super Plans
2027
Expansion Phase
- •International rollout across Australia, EU, and US markets
- •Publish peer-reviewed results from the tagging system's outcome data
- •Enable enterprise adoption and NHS integration readiness
- •Expand clinic analytics, benchmarking, and outcome reporting features
- •Publish large-scale clinical outcome data demonstrating impact and ROI
- •Position BodySync as the global standard for digital MSK treatment planning
Future Vision
BodySync's self-learning tagging system is building the foundation for a global clinical intelligence platform.
Data Collection
Each plan has various tags which provides us with ongoing, anonymous data
Super Plans
Optimised treatment pathways built from aggregated, anonymised results across thousands of users
Precision Care
Identifying the most effective treatments for specific demographics and activity profiles
Every treatment plan contributes data back into the system, allowing BodySync to analyse real-world outcomes and continuously refine its recommendations. This process enables thousands of peer-reviewed research findings to be tested and validated in everyday practice - bridging the gap between academic evidence and real-world application.
As the dataset grows, BodySync will identify the most effective treatment combinations for specific demographics and activity profiles - for example, determining which interventions work best for a female recreational runner aged 50–55 with Achilles tendinopathy and a history of rupture.
This precision will enable clinicians to deliver evidence-based care that's personalised to a level never achieved before - with predictable outcomes.
The evolving intelligence within BodySync will generate "Super Plans": continuously improving, data-driven treatment pathways. Once established, this learning dataset will form a unique competitive moat that will be extremely difficult for others to replicate.
By continuously learning from real-world data, BodySync aims to become the standard digital treatment-planning tool for MSK clinicians worldwide.
Investment Opportunity
A tax-efficient investment opportunity offering up to 50% income tax relief and capital gains exemptions under the UK SEIS scheme.
Funding Status
£25,000 already committed toward the £150,000 target, demonstrating early investor confidence and momentum in the round.
Purpose of the Raise
This round will fund BodySync's next stage of commercial growth - expanding beyond pilot sites and launching the first generation of Super Plans into the UK private MSK market.
What the Investment Enables
1. Product Development & Refinement
- • Finalise the commercial-ready version of BodySync.
- • Enhance tagging and analytics features to support Super Plan creation.
- • Improve integrations with major clinic management and exercise software systems.
2. Market Expansion & Customer Growth
- • Convert 25 pilot clinics (40+ users) into paying customers.
- • Launch marketing campaigns targeting private MSK clinics across the UK.
- • Establish referral and affiliate partnerships with clinic networks and industry partners.
3. Growth Preparation - Super Plan Commercialisation
- • Launch and monetise Super Plans as premium evidence-based templates.
- • Gather data insights from early adopters to support ongoing AI training.
- • Build the foundation for a larger Series A growth round in 2027.
Fund Allocation
| Category | Allocation | Purpose |
|---|---|---|
| Product Development | ~40% | Final refinement, Super Plan infrastructure, system scalability, Strengthen integrations with major practice management systems and exercise prescription platforms |
| Marketing & Clinic Acquisition | ~35% | Campaigns, content, events, partnerships |
| Data & Analytics | ~25% | Outcome tracking, Super Plan validation, feedback systems |
Why Now
- • 25 clinics and 40+ users already onboarded and testing BodySync.
- • Strong early feedback from clinicians - proven demand for faster, evidence-based plan generation.
- • Unique first-mover advantage in AI-driven MSK care planning.
- • SEIS eligibility provides investors with substantial tax incentives and early equity in a high-growth market.
This raise will take BodySync from pilot validation to scalable commercial success - expanding across the UK private MSK sector and establishing the foundation for data-driven Super Plans.
Founder
.png)
Charlie Holt
Charlie brings 13 years of clinical experience as a physiotherapist and is the founder of seven businesses, including two physiotherapy companies comprising nine clinics.
His ventures span physiotherapy, sporting performance, education and digital compliance - giving him a unique blend of clinical expertise and commercial acumen.
BodySync was created to solve challenges he identified firsthand in his own clinics, particularly the issue of physiotherapists underbooking patients even when further treatment was clinically indicated.
Charlie's deep sector insight and proven track record in scaling service-based businesses position BodySync for rapid growth and adoption across the UK MSK market.
Ready to Learn More?
Download our investor deck or contact us to discuss partnership opportunities.